7 Jan 2013 16:10
For immediate release | 7 January 2013 |
Futura Medical plc
("Futura" or "the Company")
Statement re Share Price Movement
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, notes the recent movement in the Company's share price.
Futura confirms that negotiations are progressing well for the re-licensing of CSD500, the Company's novel condom. While the Board is confident of re-licensing the product to one or more of the world's major condom distributors or healthcare companies, there is no guarantee that a deal or deals will be signed or that, if they are, the terms will reflect management's expectations of the value of the product.
Futura also confirms that progress towards the award of a new CE Mark for CSD500 is on track. Further updates will be provided in due course.
For any further information please contact:
Futura Medical plc | + 44 (0) 1483 685 670 |
James Barder, Chief Executive Officer Mail to: James.Barder@futuramedical.com | www.futuramedical.com |
Nomura Code Securities Limited | + 44 (0) 20 7776 1200 |
Phil Walker / Giles Balleny | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)